Bradykinin and its role in osteoarthritis

Reumatismo

Volumn 65, Issue 3, 2013, Pages 97-104

  De Falco, L ^a   Fioravanti, A ^a   Galeazzi, M ^a   Tenti, S ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bradykinin; Bradykinin B2receptor antagonists; Fasitibant; Icatibant; Osteoarthritis

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; CALCITONIN GENE RELATED PEPTIDE; CYCLOOXYGENASE 2; FASITIBANT; ICATIBANT; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; KININ DERIVATIVE; MEN 16132; PLACEBO; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CARTILAGE CELL; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; GENOTYPE; HUMAN; HYPERALGESIA; INFLAMMATION; KNEE OSTEOARTHRITIS; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SYNOVIAL FLUID; SYNOVITIS; SYNOVIUM;

BRADYKININ; HUMANS; INFLAMMATION; OSTEOARTHRITIS; RECEPTORS, BRADYKININ;

EID: 84880689197     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: 10.4081/reumatismo.2013.97     Document Type: Article

References (59)

1. Zhang Y, Jordan JM. Epidemiology of osteo-arthritis. Clin Geriatr Med. 2010; 26: 355-69.
2. Bijlsma JW, Berenbaum F, Lafeber FP. Osteo-arthritis: an update with relevance for clinical practice. Lancet. 2011; 18: 2115-26.
3. Martel-Pelletier J. Pathophysiology of osteo-arthritis. Osteoarthritis Cartilage. 2004; 12 (Suppl. A): 31S-33S.
4. Goldring SR, Goldring MB. The role of cyto-kines in cartilage matrix degeneration in os-teoarthritis. Clin Orthop Relat Res. 2004; 427: 27-36.
5. Daheshia M, Yao JQ. The Interleukin 1β path-way in the pathogenesis of osteoarthritis. J Rheumatol. 2008; 35: 2306-12.
6. Cawston TE, Young DA. Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res. 2010; 339: 221-35.
7. Wenham CY, Conaghan PG. New horizons in osteoarthritis. Age Ageing. 2013; 42: 272-8.
8. Meini S, Maggi CA. Knee osteoarthritis: a role for bradykinin? Inflamm Res. 2008; 57: 351-61.
9. Bhoola KD, Figueroa CD, Worthy K. Bioreg-ulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992; 44: 1-80.
10. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and fu-ture pharmacological targets. J Pharmacol Sci. 2005; 99: 6-38.
11. Foord SM, Bonner TI, Neubig RR, et al. In-ternational Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev. 2005; 57: 279-88.
12. Regoli D, Barabé J. Pharmacology of bradyki-nin and related kinins. Pharmacol Rev. 1980; 32: 1-46.
13. Chen S, Zhou Y, Li J, et al. The effect of Bra-dykinin B2 receptor polymorphism on the susceptibility and severity of osteoarthritis in a Chinese Cohort. J Biomed Biotechnol. 2012; 2012: 597-637.
14. Melmon KL, Webster ME, Goldfinger SE, Seegmiller JE. The presence of a kinin in in-flammatory synovial effusion from arthritides of varying etiologies. Arthritis Rheum. 1967; 10: 13-20.
15. Eisen V. Plasma kinins in synovial exudates. Br J Exp Pathol. 1970; 51: 322-7.
16. Bond AP, Breipohl G, Worthy K, et al. Metab-olism and characterisation of kinins and Hoe 140 (kinin antagonist) in the synovial fluid of patients with inflammatory joint diseases. Agents Actions Suppl. 1992; 38: 582-9.
17. Nishimura M, Segami N, Kaneyama K, et al. Relationships between pain-related mediators and both synovitis and joint pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 94: 328-32.
18. Meini S, Bellucci F, Cucchi P, et al. Bradyki-nin contents in the synovial fluid from patients affected by knees osteoarthritis. Proceedings of Kinin 2012 Conference; 2012 Jun 21-23p; Paris.
19. Steranka LR, Manning DC, DeHaas CJ, et al. Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. Proc Natl Acad Sci USA. 1988; 85: 3245-9.
20. Dray A, Bettaney J, Forster P, Perkins MN. Bradykinin-induced stimulation of afferent fibres is mediated through protein kinase C. Neurosci Lett. 1988; 91: 301-7.
21. Dray A. Kinins and their receptors in hyper-algesia. Can J Physiol Pharmacol. 1997; 75: 704-12.
22. Cesare P, McNaughton P. A novel heat-activat-ed current in nociceptive neurons and its sen-sitization by bradykinin. Proc Natl Acad Sci USA. 1996; 93: 15435-9.
23. Cesare P, McNaughton P. Peripheral pain mechanisms. Curr Opin Neurobiol. 1997; 7: 493-9.
24. Premkumar LS, Ahern GP. Induction of vanil-loid receptor channel activity by protein ki-nase C. Nature. 2000; 408: 985-90.
25. Chuang HH, Prescott ED, Kong H, et al. Bra-dykinin and nerve growth factor release the capsaicin receptor from PtdIns (4,5) P2-medi-ated inhibition. Nature. 2001; 41: 957-62.
26. Averbeck B, Rudolphi K, Michaelis M. Osteo-arthritic mice exhibit enhanced prostaglandin E2 and unchanged calcitonin gene-related peptide release in a novel isolated knee joint model. J Rheumatol. 2004; 31: 2013-20.
27. Gotoh S, Onaya J, Abe M, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993; 52: 817-22.
28. Davis AJ, Perkins MN. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. Br J Pharmacol. 1994; 113: 63-8.
29. 2 receptors. Br J Pharmacol. 1996; 118: 2206-12.
30. Tonussi CR, Ferreira SH. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain. 1999; 82: 81-7.
31. Green PG, Luo J, Heller PH, Levine JD. Ef-fect of E-type prostaglandins on bradykinin-induced plasma extravasation in the knee joint of the rat. Eur J Pharmacol. 1994; 252: 127-32.
32. Lo EJ, Green PG, Miao FJ, et al. Bradykinin-induced neurogenic migration of neutrophils into the rat knee joint. Neuroreport. 1999; 10: 3821-4.
33. Grond S, Demopulos G, Herz J, Pierce Palmer P. Inhibition of synovial plasma extravasation by preemptive administration of an antiin-flammatory irrigation solution in the rat knee. Anesth Analg. 2001; 92: 1301-6.
34. Cruwys SC, Kidd BL, Mapp PI, et al. The effects of calcitonin gene-related peptide on formation of intra-articular oedema by inflam-matory mediators. Br J Pharmacol. 1992; 107: 116-9.
35. Cambridge H, Brain SD. Mechanism of bra-dykinin-induced plasma extravasation in the rat knee joint. Br J Pharmacol. 1995; 115: 641-7.
36. Iwanaga T, Shikichi M, Kitamura H, et al. Morphology and functional roles of synovio-cytes in the joint. Arch Histol Cytol. 2000; 63: 17-31.
37. Bathon JM, Manning DC, Goldman DW, et al. Characterization of kinin receptors on hu-man synovial cells and upregulation of recep-tor number by interleukin-1. J Pharmacol Exp Ther. 1992; 260: 384-92.
38. Uhl J, Singh S, Brophy L, et al. Role of brady-kinin in inflammatory arthritis: identification and functional analysis of bradykinin recep-tors on human synovial fibroblasts. Immuno-pharmacology. 1992; 23: 131-8.
39. Cassim B, Naidoo S, Ramsaroop R, Bhoola KD. Immunolocalization of bradykinin recep-tors on human synovial tissue. Immunophar-macology. 1997; 36: 121-5.
40. Bellucci F, Cucchi P, Catalani C, et al. Novel effects mediated by bradykinin and pharma-cological characterization of bradykinin B2 receptor antagonism in human synovial fi-broblasts. Br J Pharmacol. 2009; 158: 1996-2004.
41. Fahey JV, Ciosek CP Jr, Newcombe DS. Hu-man synovial fibroblasts: the relationships between cyclic AMP, bradykinin, and prosta-glandins. Agents Actions. 1977; 7: 255-64.
42. Fahey JV, Newcombe DS. The effect of 7-oxa- 13 prostynoic acid in the mechanism of action of bradykinin in human synovial fibroblasts. Prostaglandins. 1978; 15: 333-42.
43. Meini S, Cucchi P, Tinti L, et al. Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E2 release and cyclooxygenase 2 expression in human fibro-blast-like synoviocytes. Naunyn Schmiede-bergs Arch Pharmacol. 2012; 385: 777-86.
44. Meini S, Cucchi P, Catalani C, et al. Bradyki-nin and B2 receptor antagonism in rat and hu-man articular chondrocytes. Br J Pharmacol. 2011; 162: 611-22.
45. Bonnet CS, Walsh DA. Osteoarthritis, an-giogenesis and inflammation. Rheumatology (Oxford). 2005; 44: 7-16.
46. Meini S, Bellucci F, Catalani C, et al. parison of the molecular interactions of two antagonists, MEN16132, or Icatibant, at the human kinin B2 receptor. Br J Pharmacol. 2011; 162: 1202-12.
47. Rhaleb NE, Rouissi N, Jukic D, et al. Phar-macological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-(Hyp3, Thi5, D-Tic7, Qic8) bradykinin). Eur J Pharmacol. 1992; 210: 115-20.
48. Dziadulewicz EK. Non-peptide ligands for bradykinin receptors. Expert Opin Ther Pat-ent. 2005; 15: 829-59.
49. Abraham WM, Scuri M, Farmer SG. Peptide and non-peptide bradykinin receptor antago-nists: role in allergic airway disease. Eur J Pharmacol. 2006; 533: 215-21.
50. Fincham CI, Bressan A, Paris M, et al. Bra-dykinin receptor antagonists- a review of the patent literature. Expert Opin Ther Pat. 2009; 19: 919-41.
51. Cucchi P, Meini S, Bressan A, et al. MEN16132, a novel potent and selective non-peptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and mo-lecular characterization. Eur J Pharmacol. 2005; 528: 7-16.
52. Meini S, Cucchi P, Bellucci F, et al. Com-parative antagonist pharmacology at the native mouse bradykinin B2 receptor: radioligand binding and smooth muscle contractility stud-ies. Br J Pharmacol. 2007; 150: 313-20.
53. Meini S, Cucchi P, Catalani C, et al. Pharma-cology characterization of the bradykinin B2 receptor antagonist MEN16132 in rat in vitro bioassays. Eur J Pharmacol. 2009; 615: 10-6.
54. Meini S, Cucchi P, Catalani C, et al. Radio-ligand binding characterization of the brady-kinin B2 receptor in the rabbit and pig ileal smooth musce. Eur J Pharmacol. 2010; 635: 34-9.
55. 2 receptor antagonist, on nociceptive response in mono-sodium iodoacetate-induced experimental osteoarthritis in rats. J Pharmacol Exp Ther. 2009; 331: 1025-32.
56. Flechtenmacher J, Talke M, Veith D, et al. Bra-dykinin-receptor-inhibition-a therapeutic op-tion in osteoarthritis? Osteoarthr Cartil. 2004; 12 (Suppl. 137): S332.
57. Song IH, Althoff CE, Hermann KG, et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor-2 antago-nist in painful knee osteoarthritis compared to magnetic resonance imaging. Ann Rheum Dis. 2009; 68: 75-83.
58. Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone. 2012; 51: 297-311.
59. Fioravanti A. I condroprotettori: meccanismo d'azione e problemi aperti. Reumatismo. 1993; 45: 306-18.